Many clinical trials have been conducted assessing the use of anti-GPIIb/IIIa inhibitors in the treatment of acute ischemic stroke or the prevention of stroke [reviewed for tirofiban in (89)]. This evidence concerns the gene ITGA2B and Stroke.